Exelixis (EXEL) Competitors $39.15 +0.60 (+1.56%) As of 04/30/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EXEL vs. ALNY, BIIB, UTHR, BMRN, INCY, NBIX, EXAS, RGEN, HALO, and MDGLShould you be buying Exelixis stock or one of its competitors? The main competitors of Exelixis include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Exelixis vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Neurocrine Biosciences Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Exelixis (NASDAQ:EXEL) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, community ranking, profitability and dividends. Do institutionals and insiders believe in ALNY or EXEL? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by insiders. Comparatively, 2.9% of Exelixis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts rate ALNY or EXEL? Alnylam Pharmaceuticals presently has a consensus price target of $315.58, indicating a potential upside of 19.88%. Exelixis has a consensus price target of $37.59, indicating a potential downside of 3.99%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Exelixis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 21 Buy rating(s) 0 Strong Buy rating(s) 2.77Exelixis 2 Sell rating(s) 6 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.47 Does the MarketBeat Community favor ALNY or EXEL? Alnylam Pharmaceuticals received 542 more outperform votes than Exelixis when rated by MarketBeat users. Likewise, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 68.58% of users gave Exelixis an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes116476.28% Underperform Votes36223.72% ExelixisOutperform Votes62268.58% Underperform Votes28531.42% Which has more volatility & risk, ALNY or EXEL? Alnylam Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500. Comparatively, Exelixis has a beta of 0.57, indicating that its share price is 43% less volatile than the S&P 500. Which has higher earnings and valuation, ALNY or EXEL? Exelixis has lower revenue, but higher earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B15.23-$278.16M-$2.17-121.31Exelixis$2.17B4.97$521.27M$1.7722.12 Does the media favor ALNY or EXEL? In the previous week, Alnylam Pharmaceuticals had 1 more articles in the media than Exelixis. MarketBeat recorded 24 mentions for Alnylam Pharmaceuticals and 23 mentions for Exelixis. Exelixis' average media sentiment score of 1.31 beat Alnylam Pharmaceuticals' score of 1.02 indicating that Exelixis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 17 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive Exelixis 16 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ALNY or EXEL more profitable? Exelixis has a net margin of 24.04% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Exelixis' return on equity of 23.52% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Exelixis 24.04%23.52%17.95% SummaryAlnylam Pharmaceuticals and Exelixis tied by winning 9 of the 18 factors compared between the two stocks. Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EXEL vs. The Competition Export to ExcelMetricExelixisBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$10.79B$3.00B$5.57B$7.83BDividend YieldN/A1.89%5.11%4.21%P/E Ratio22.1230.4222.4418.48Price / Sales4.97498.92394.10103.59Price / Cash18.22168.6838.1834.62Price / Book4.883.206.774.25Net Income$521.27M-$72.35M$3.22B$248.23M7 Day Performance5.21%1.46%1.48%0.89%1 Month Performance7.58%8.79%3.99%3.53%1 Year Performance78.56%-22.36%16.20%5.08% Exelixis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EXELExelixis4.0788 of 5 stars$39.15+1.6%$37.59-4.0%+66.9%$10.79B$2.17B22.121,220Short Interest ↑Analyst RevisionPositive NewsALNYAlnylam Pharmaceuticals4.3115 of 5 stars$232.75-0.8%$315.58+35.6%+82.9%$30.28B$2.25B-107.262,000Analyst DowngradePositive NewsBIIBBiogen4.6901 of 5 stars$116.49-1.8%$213.15+83.0%-43.6%$17.05B$9.68B10.418,720Analyst DowngradeAnalyst RevisionUTHRUnited Therapeutics4.9052 of 5 stars$284.25-0.2%$395.67+39.2%+29.3%$12.77B$2.88B12.48980Earnings ReportAnalyst RevisionNews CoveragePositive NewsGap UpBMRNBioMarin Pharmaceutical4.9208 of 5 stars$58.65-0.9%$94.00+60.3%-21.1%$11.19B$2.85B26.663,080Upcoming EarningsPositive NewsINCYIncyte4.7148 of 5 stars$56.80-2.4%$74.69+31.5%+20.4%$10.99B$4.24B210.382,320Earnings ReportAnalyst ForecastNBIXNeurocrine Biosciences4.8613 of 5 stars$100.68-0.7%$161.86+60.8%-21.7%$9.96B$2.36B30.601,200Upcoming EarningsAnalyst ForecastAnalyst RevisionEXASExact Sciences4.3999 of 5 stars$43.10+3.7%$69.25+60.7%-23.1%$8.01B$2.76B-7.746,400RGENRepligen4.8875 of 5 stars$131.64+1.3%$176.82+34.3%-16.0%$7.39B$634.44M-258.122,020Earnings ReportAnalyst UpgradeNews CoveragePositive NewsHALOHalozyme Therapeutics4.0044 of 5 stars$57.29-2.6%$62.89+9.8%+61.2%$7.08B$1.02B16.70390Upcoming EarningsInsider TradeAnalyst RevisionMDGLMadrigal Pharmaceuticals3.7477 of 5 stars$295.02-2.2%$378.44+28.3%+63.7%$6.51B$180.13M-11.7690Upcoming EarningsNews CoveragePositive NewsGap Down Related Companies and Tools Related Companies Alnylam Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives BioMarin Pharmaceutical Alternatives Incyte Alternatives Neurocrine Biosciences Alternatives Exact Sciences Alternatives Repligen Alternatives Halozyme Therapeutics Alternatives Madrigal Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EXEL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EXEL Stock Free EXEL Stock Alerts